Your oncology practice delivers complex care; your billing should be just as precise. Health Med Affairs provides specialized billing and RCM for oncology practices, covering chemotherapy, infusion, radiation, drug billing, coding, claims, and denials. We turn intricate reimbursement requirements into a streamlined revenue cycle built around your practice.
Every chemotherapy drug is reviewed against the documentation, correct HCPCS J-code, dosage, units, and applicable wastage rules to prevent costly reimbursement discrepancies.
Administration services are matched to documented treatment time, sequencing, and applicable CPT codes such as 96413, 96415, 96417, 96365, and 96366.
Clinical documentation is translated into accurate oncology coding, reducing errors involving treatment intent, procedures, diagnoses, modifiers, and services that can trigger avoidable claim denials.
High-cost oncology drugs and treatment services are tracked through authorization requirements before billing, helping prevent avoidable non-payment caused by missing, expired, or mismatched approvals.
Billable drug wastage is carefully identified and reported with applicable JW or JZ modifiers, helping practices capture eligible reimbursement without creating compliance concerns.
Denials involving chemotherapy, drugs, infusions, or medical necessity are investigated at the coding and documentation level, followed by targeted appeals and payer follow-up.
Aging oncology accounts receive focused follow-up rather than routine A/R treatment, prioritizing high-dollar claims, delayed drug reimbursements, repeated payer issues, and underpaid services.
Claims and billing workflows are examined for missed administration charges, incorrect units, unbilled services, modifier mistakes, and recurring payer discrepancies that quietly drain oncology revenue.
Your oncology practice shouldn’t have to chase denied claims, correct coding errors, or track down missing reimbursements.
Let Health Med Affairs take control of the billing complexity, from chemotherapy and infusion claims to J-codes, denials, A/R, and revenue recovery, so you can capture more of the revenue your practice has already earned.
Your oncology billing needs to fit your practice,submission; it not force your practice into a generic billing workflow. Whether you run an independent oncology group, infusion center, hematology-oncology practice, radiation oncology facility, or hospital-affiliated cancer program, Health Med Affairs adapts its billing and RCM approach around the services you actually provide.
Chemotherapy, immunotherapy, biologics, injections, E/M services, drug administration, and complex infusion billing.
Specialized billing workflows for hematology and oncology services, including treatment-related procedures, injections, infusions, and recurring patient encounters.
Accurate administration, drug, dosage, unit, time, and documentation review across high-value infusion encounters.
Specialized support for radiation treatment, planning, simulation, delivery, management, and associated billing workflows.
In oncology, getting the claim paid is only part of the equation. Getting the drug reimbursed correctly is where significant revenue can be won or lost.
A chemotherapy or biologic claim can involve an expensive drug, specific HCPCS coding, dosage calculations, units administered, wastage, modifiers, payer reimbursement rules, and supporting documentation.
One discrepancy can affect the economics of the entire encounter.
Drug charges are reviewed against the documented medication, applicable HCPCS code, dosage, and billed units.
Applicable discarded amounts and JW/JZ reporting requirements are evaluated against the documentation and billing circumstances.
Expensive oncology drug claims receive the level of scrutiny they deserve rather than being treated like routine office claims.
Reimbursement can be compared against expected payment to identify discrepancies that may otherwise remain hidden.
The objective isn't simply to submit more claims. It's to make sure the revenue attached to every eligible oncology drug is accurately represented, supported, and pursued.
A prior authorization isn’t useful if it doesn’t accurately support the treatment actually being administered and billed.
That’s why authorization management needs to go beyond simply asking whether an approval exists.
Patient benefits, payer requirements, treatment details, and authorization requirements are reviewed.
Authorization details are checked against the services and drugs being submitted, helping identify discrepancies before they become avoidable reimbursement problems.
Changes involving medication, dosage, treatment cycles, or regimen requirements are monitored so authorization information remains aligned with the treatment plan.
Authorization-related denials are investigated to determine whether the issue involves eligibility, documentation, authorization scope, treatment changes, or payer requirements.
The result: a tighter connection between what the oncologist orders, what the patient receives, what the payer authorizes, and what ultimately gets billed.
A claim marked “paid” isn't necessarily a claim paid correctly. That's where many revenue opportunities disappear.
Health Med Affairs can examine high-value oncology claims for discrepancies between expected and actual reimbursement.
Was the expensive oncology drug reimbursed according to the applicable payment methodology?
Were eligible chemotherapy or infusion administration services reimbursed appropriately?
Did the payer reimburse only part of the expected amount without a valid explanation?
Do contractual or payer adjustments appear inconsistent with the claim's expected reimbursement?
Are similar underpayments appearing repeatedly across oncology claims?
Are payments falling below contracted or expected reimbursement levels across comparable oncology services?
Claim Paid
Payment Reviewed
Variance Identified
Payer Investigated
Documentation Gathered
Recovery Pursued
Your specialty mix, systems, payers, workflows, treatment services, and existing billing process are reviewed before establishing the working model.
The review focuses on oncology-specific issues such as drug billing, administration coding, authorization gaps, denials, A/R, underpayments, and missed charges.
Billing procedures are aligned with your practice's services, documentation, payer requirements, and operational structure.
Charges, codes, drug units, documentation, modifiers, and applicable billing requirements are reviewed before claims move forward.
Claims are monitored, denials are addressed, outstanding balances are followed up, and high-value accounts receive focused attention.
Performance isn't treated as a one-time cleanup. Recurring denial patterns, payment discrepancies, and workflow weaknesses can be identified as the revenue cycle continues.